{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:09:54Z","timestamp":1778940594540,"version":"3.51.4"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2018-04737"],"award-info":[{"award-number":["RGPIN-2018-04737"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["946085"],"award-info":[{"award-number":["946085"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014116","name":"Ontario Veterinary College, University of Guelph","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201076","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T07:44:59Z","timestamp":1761983099000},"page":"201076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models"],"prefix":"10.1016","volume":"33","author":[{"given":"Jacob G.E.","family":"Yates","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa E.","family":"Bogle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena S.B.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arielle N.","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madison E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"McAusland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Susta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalil","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel T.","family":"Workenhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-2406","authenticated-orcid":false,"given":"Sarah K.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201076_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2847","article-title":"An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination","volume":"15","author":"Carre\u00f1o","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.201076_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01538-22","article-title":"Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice","volume":"10","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.omton.2025.201076_bib3","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41541-024-00870-8","article-title":"Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges","volume":"9","author":"Warner","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omton.2025.201076_bib4","doi-asserted-by":"crossref","first-page":"103219","DOI":"10.1016\/j.isci.2021.103219","article-title":"Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease","volume":"24","author":"Warner","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.omton.2025.201076_bib5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-18-0220","article-title":"Combining vascular normalization with an oncolytic virus enhances immunotherapy in a preclinical model of advanced-stage ovarian cancer","volume":"25","author":"Matuszewska","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201076_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2024.1325558","article-title":"Recombinant Newcastle disease viruses expressing immunological checkpoint inhibitors induce a pro-inflammatory state and enhance tumor-specific immune responses in two murine models of cancer","volume":"15","author":"Santry","year":"2024","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omton.2025.201076_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omto.2021.01.009","article-title":"Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models","volume":"20","author":"McAusland","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201076_bib8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201076_bib9","doi-asserted-by":"crossref","first-page":"14340","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201076_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ebiom.2019.10.032","article-title":"Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma","volume":"49","author":"Vijayakumar","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omton.2025.201076_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymthe.2005.08.016","article-title":"Phase I\/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme","volume":"13","author":"Freeman","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201076_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009336","article-title":"Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV\u2013GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors","volume":"12","author":"Davar","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib13","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1158\/1078-0432.CCR-05-2038","article-title":"A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization","volume":"12","author":"Laurie","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201076_bib14","first-page":"635","article-title":"Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68\/H)","volume":"19","author":"Csatary","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2025.201076_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virusres.2017.03.003","article-title":"Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy","volume":"233","author":"Xu","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.omton.2025.201076_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jphs.2016.03.012","article-title":"Recombinant Newcastle disease virus (NDV\/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy","volume":"132","author":"Wu","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.omton.2025.201076_bib17","doi-asserted-by":"crossref","DOI":"10.3791\/63817","article-title":"Production of High-titer Recombinant Newcastle Disease Virus from Allantoic Fluid","author":"Yates","year":"2022","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omton.2025.201076_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.omto.2019.06.001","article-title":"Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine","volume":"14","author":"Xu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201076_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01677-19","article-title":"Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines","volume":"94","author":"Vijayakumar","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2025.201076_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201076_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2025.201076_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2025.201076_bib23","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity and Immune Correlates of Anti-PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201076_bib24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 Immune Checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2025.201076_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14802","article-title":"A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer","volume":"8","author":"Betancur","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201076_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature18935","article-title":"CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis","volume":"536","author":"Kojima","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201076_bib27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nm.3965","article-title":"CD47 blockade as another immune checkpoint therapy for cancer","volume":"21","author":"Vonderheide","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201076_bib28","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell\u2013mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2025.201076_bib29","article-title":"Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib30","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.3390\/cancers15215229","article-title":"CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer","volume":"15","author":"Lau","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2025.201076_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100351","article-title":"Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry","volume":"2","author":"Skordos","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omton.2025.201076_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40425-017-0235-4","article-title":"Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy","volume":"5","author":"Sckisel","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib33","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1038\/s41598-019-40241-1","article-title":"Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells","author":"Lian","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.201076_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003464","article-title":"Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity","volume":"9","author":"Chen","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib35","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1158\/1535-7163.MCT-20-0902","article-title":"Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity","volume":"20","author":"Harper","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2025.201076_bib36","first-page":"840","article-title":"Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity","volume":"40","author":"Fournier","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2025.201076_bib37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","article-title":"TNF-\u03b1\/NF-\u03baB\/Snail pathway in cancer cell migration and invasion","volume":"102","author":"Wu","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib39","doi-asserted-by":"crossref","first-page":"15160","DOI":"10.1038\/s41598-019-51465-6","article-title":"Antiviral interferons induced by Newcastle disease virus (NDV) drive a tumor-selective apoptosis","volume":"9","author":"Ginting","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.201076_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13567-024-01312-y","article-title":"The haemagglutinin-neuraminidase protein of velogenic Newcastle disease virus enhances viral infection through NF-\u03baB-mediated programmed cell death","volume":"55","author":"Lu","year":"2024","journal-title":"Vet. Res."},{"key":"10.1016\/j.omton.2025.201076_bib41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.vetmic.2017.03.002","article-title":"Newcastle disease virus-like particles induce DC maturation through TLR4\/NF-\u03baB pathway and facilitate DC migration by CCR7-CCL19\/CCL21 axis","volume":"203","author":"Qian","year":"2017","journal-title":"Vet. Microbiol."},{"key":"10.1016\/j.omton.2025.201076_bib42","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00705-016-2950-4","article-title":"The LXR ligand GW3965 inhibits Newcastle disease virus infection by affecting cholesterol homeostasis","volume":"161","author":"Sheng","year":"2016","journal-title":"Arch. Virol."},{"key":"10.1016\/j.omton.2025.201076_bib43","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2025.201076_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.99","article-title":"Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells","volume":"4","author":"Cao","year":"2021","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.omton.2025.201076_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1304374","article-title":"YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells","volume":"14","author":"von Ofen","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201076_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/cas.13468","article-title":"Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy","volume":"109","author":"Xu","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2025.201076_bib47","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00262-025-04032-0","article-title":"Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy","volume":"74","author":"Reischer","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2025.201076_bib48","article-title":"Advances in Anti-Tumor Treatments Targeting the CD47\/SIRP\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0092-8674(01)00455-X","article-title":"Regulation of T cell immunity by dendritic cells","volume":"106","author":"Lanzavecchia","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201076_bib50","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.it.2007.03.008","article-title":"Duration, combination and timing: the signal integration model of dendritic cell activation","volume":"28","author":"Macagno","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib51","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/1521-4141(200207)32:7<2046::AID-IMMU2046>3.0.CO;2-M","article-title":"T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification","volume":"32","author":"Langenkamp","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib52","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/342559a0","article-title":"Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen","volume":"342","author":"Pircher","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201076_bib53","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omto.2021.09.005","article-title":"CD47-targeted cancer immunogene therapy: Secreted SIRP\u03b1-Fc fusion protein eradicates tumors by macrophage and NK cell activation","volume":"23","author":"Billerhart","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2025.201076_bib54","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1002\/cam4.2332","article-title":"Engineering macrophages to phagocytose cancer cells by blocking the CD47\/SIRP\u0251 axis","volume":"8","author":"Yang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2025.201076_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity","volume":"10","author":"Van Duijn","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib56","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","article-title":"Role of PD-1 during effector CD8 T cell differentiation","volume":"115","author":"Ahn","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.201076_bib57","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omton.2025.201076_bib58","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","article-title":"Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein \u03b1 Signaling","volume":"47","author":"Xu","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2025.201076_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109546","article-title":"Disruption of CD47-SIRP\u03b1 signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells","volume":"27","author":"Zimarino","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.omton.2025.201076_bib60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201076_bib61","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/cmi.2017.143","article-title":"IDO1 in cancer: a Gemini of immune checkpoints","volume":"15","author":"Zhai","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201076_bib63","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201076_bib64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib65","doi-asserted-by":"crossref","first-page":"9464","DOI":"10.1038\/s41467-024-53706-3","article-title":"Prostaglandin E2-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells","volume":"15","author":"Punyawatthananukool","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201076_bib66","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 BLOCKADE ENHANCES T CELL MIGRATION TO TUMORS BY ELEVATING IFN-\u03b3 INDUCIBLE CHEMOKINES","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201076_bib67","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.4049\/jimmunol.0904114","article-title":"Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma","volume":"184","author":"Pilon-Thomas","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2025.201076_bib68","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2025.201076_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111342","article-title":"In vivo G-CSF treatment activates the GR-SOCS1 axis to suppress IFN-\u03b3 secretion by natural killer cells","volume":"40","author":"Zhao","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2025.201076_bib70","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omton.2025.201076_bib71","article-title":"In Situ Tumor Vaccine Expressing Anti-CD47 Antibody Enhances Antitumor Immunity","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201076_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009768","article-title":"Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity","volume":"12","author":"Zhao","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib73","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201076_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1878-0261.12628","article-title":"A SIRP\u03b1-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer","volume":"14","author":"Huang","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.omton.2025.201076_bib75","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41392-023-01683-2","article-title":"Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2025.201076_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009473","article-title":"Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201076_bib77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.omtm.2017.10.004","article-title":"Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer","volume":"9","author":"Santry","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2025.201076_bib78","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41434-023-00385-2","article-title":"Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis","volume":"32","author":"Rghei","year":"2025","journal-title":"Gene Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:45Z","timestamp":1778938665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925001456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950329925001456"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201076","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic Newcastle-disease-virus-mediated CD47 blockade in preclinical melanoma and pancreatic cancer models","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201076"}}